Profound Medical Corp.
PROFHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Profound Medical Corp. focuses on Medical Devices services and products. Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company carries a $251.8M market cap, placing it firmly in the micro-cap category. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
Market Cap
$251.8M
Beta
0.50
P/E (TTM)
—
P/E (Fwd)
-11.72
EPS (TTM)
$-0.99
EPS (Fwd)
$-0.59
ROE
-73.5%
ROA
-39.5%
Cash
$38.3M
Total Debt
$7.4M
Free CF
-$24.8M
52W Change
68.9%
Annual Financials
Cash vs Debt
Where PROF stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PROF finished 0.89% above its 150-day moving average ($6.76) and 1.16% below its 200-day moving average ($6.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PROF overbought or oversold?
At the September 3, 2026 close, PROF's RSI(14) was 54.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $38.3M in cash and $7.4M in debt, PROF maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$24.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -73.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $6.7M (2022) to $16.1M (2025), reflecting a 141% increase over the period.
With a beta below 0.7, Profound Medical Corp. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, PROF has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Profound Medical Corp.'s trajectory.